Don't know. Pretty hard hit today on so-called positive news. Unless we see insiders buying and buying big (not this 10000 share #$%$), I think SNTA goes nowhere and probably lower as they will need more cash relatively soon.
I attended the oral presentation at Chicago today. There were I'd estimate 500 in audience. The general impression from the audience and the discussant were positive and they used words like "exciting data" etc. e only concern from the discussant was the the incorporation of 6 months since metastatic disease. She felt that there is not a clear scientific basis for this. The TTNL data for the exploratory analysis was very mpressive. The KRas correlative is trending to favor D+G arm but currently is not significant. The jury is still out on this. She also concluded the phase III design is appropriate and will incorporate sme of the same stratification.
So bottom line is that data looks very good and I firmly believe the market over reacted here.